Indian generics giant Dr. Reddy's Laboratories is prepping for the launch of its U.S. over-the-counter business. Today, the company got the FDA's final OK for its version of Zantac in a 150 mg dose. The company previously had won FDA approval for a 75 mg version.
Dr. Reddy's announced in mid-May that it would start a division focusing on store-brand OTC products. The company's U.S. chief, Mark Hartman, hailed the ranitidine approval as the first of several expected in the near term. No word yet on when the products will be rolled out.
- check out the release
- read the report from Hemscott
Related Articles:
Problems with Zantac, Tagamet? Report
Dr. Reddy's make risky biogenerics move. Report
Dr. Reddy's launches new drug-development company. ReportÂ